Caveats to aggressive lowering of lipids by specific statins

International Journal of Cardiology

Volumn 154, Issue 2, 2012, Pages 97-101

  Koh, Kwang Kon ^a   Lim, Soo ^b   Sakuma, Ichiro ^c   Quon, Michael J ^d  

^a Gachon University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Hokko Memorial Clinic   (Japan)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Cardiovascular diseases; Diabetes mellitus; Statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

AORTA STENOSIS; ATHEROSCLEROSIS; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG LABELING; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84855833067     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.09.002     Document Type: Editorial

References (50)

1. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. D. Steinberg, C.K. Glass, and J.L. Witztum Evidence mandating earlier and more aggressive treatment of hypercholesterolemia Circulation 118 2008 672 677
3. A.A. Alsheikh-Ali, P.V. Maddukuri, H. Han, and R.H. Karas Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials J Am Coll Cardiol 50 2007 409 418 (Pubitemid 47096680)
4. J.C. La Rosa, S.M. Grundy, and D.D. Waters Treating to new targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
5. A.B. Rossebø, T.R. Pedersen, and K. Boman Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 2008 1343 1356
6. C. Baigent, M.J. Landray, and C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
7. H. Mazume, K. Nakata, and D. Hida Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway J Hepatol 30 1999 904 910 (Pubitemid 29248993)
8. U.K. Khanzada, O.E. Pardo, C. Meier, J. Downward, M.J. Seckl, and A. Arcaro Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling Oncogene 25 2006 877 887 (Pubitemid 43237706)
9. D. Jacobs, H. Blackburn, and M. Higgins Report of the conference on low blood cholesterol: mortality associations Circulation 86 1992 1046 1060
10. G. Wannamethee, A.G. Shaper, P.H. Whincup, and M. Walker Low serum total cholesterol concentrations and mortality in middle aged British men BMJ 311 1995 409 413
11. K.M. Dale, C.I. Coleman, N.N. Henyan, J. Kluger, and C.M. White Statins and cancer risk: a meta-analysis JAMA 295 2006 74 80 (Pubitemid 43042692)
12. A.A. Alsheikh-Ali, T.A. Trikalinos, D.M. Kent, and R.H. Karas Statins, low-density lipoprotein cholesterol, and risk of cancer J Am Coll Cardiol 52 2008 1141 1147
13. K.K. Koh, and M.J. Quon The importance of considering alternative or combination strategies for lowering LDL-C Int J Cardiol 136 2009 115 119
14. K.K. Koh, I. Sakuma, and M.J. Quon Differential metabolic effects of distinct statins Atherosclerosis 215 2011 1 8
15. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
16. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials Lancet 375 2010 735 742
17. 2+ channels in rat islet beta-cells Br J Pharmacol 126 1999 1205 1213 (Pubitemid 29123757)
18. K.K. Koh, M.J. Quon, and S.H. Han Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients Atherosclerosis 204 2009 483 490
19. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, and E.K. Shin Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J Am Coll Cardiol 55 2010 1209 1216
20. K.K. Koh, M.J. Quon, and S.H. Han Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients Diabetes Care 31 2008 776 782
21. K.K. Koh, M.J. Quon, and I. Sakuma Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia Int J Cardiol 146 2011 434 437
22. K.K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res 47 2000 648 657
23. K.K. Koh, and M.J. Quon Targeting converging therapeutic pathways to overcome hypertension Int J Cardiol 132 2009 297 299
24. R. Corti, V. Fuster, and Z.A. Fayad Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging J Am Coll Cardiol 46 2005 106 112 (Pubitemid 40905137)
25. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
26. A. Egan, and E. Colman Weighing the benefits of high-dose simvastatin against the risk of myopathy N Engl J Med 365 2011 285 287
27. R.B. Goldberg, J.R. Guyton, and T. Mazzone Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study Mayo Clin Proc 81 2006 1579 1588 (Pubitemid 44871902)
28. J. Chapman Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia Eur Heart J 7 2005 F56 F62 (Suppl.)
29. O. Bayturan, S. Kapadia, and S.J. Nicholls Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol J Am Coll Cardiol 55 2010 2736 2742
30. R. Muniyappa, M. Montagnani, K.K. Koh, and M.J. Quon Cardiovascular actions of insulin Endocr Rev 28 2007 463 491 (Pubitemid 47236334)
31. H.-W. Park, T.G. Kwon, K.-Y. Kim, and J.-H. Bae Diabetes, insulin resistance and atherosclerosis surrogates in patients with coronary atherosclerosis Korean Circulation Journal 40 2010 62 67
32. A.E. Di, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
33. P. Barter, A.M. Gotto, and J.C. LaRosa Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
34. M. Miller, C.P. Cannon, and S.A. Murphy Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730 (Pubitemid 351221217)
35. A.M. Tonkin, and L. Chen Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial Circulation 122 2010 850 852
36. E.Y. Chew, W.T. Ambrosius, and M.D. Davis Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 2010 233 244
37. J.W. Son, K.K. Koh, and S.M. You Effects of simvastatin alone or combined with ramipril on nitric oxide bioactivity and inflammation markers in hypercholesterolemic patients Korean Circulation Journal 33 2003 1053 1059
38. K.K. Koh, M.J. Quon, and S.H. Han Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients Circulation 110 2004 3687 3692 (Pubitemid 39665258)
39. K.K. Koh, M.J. Quon, and S.H. Han Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia J Am Coll Cardiol 45 2005 1649 1653 (Pubitemid 40704501)
40. K.K. Koh, S.H. Han, and M.J. Quon Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions J Am Coll Cardiol 46 2005 1978 1985 (Pubitemid 41713578)
41. S.H. Han, M.J. Quon, J. Kim, and K.K. Koh Adiponectin and cardiovascular disease: response to therapeutic interventions J Am Coll Cardiol 49 2007 531 538 (Pubitemid 46177440)
42. K.K. Koh, M.J. Quon, R.S. Rosenson, W.-J. Chung, and S.H. Han Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates Int J Cardiol 124 2008 149 159 (Pubitemid 351173369)
43. K.K. Koh, P.C. Oh, and M.J. Quon Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res 81 2009 649 659
44. K.K. Koh, S.H. Han, P.C. Oh, E.K. Shin, and M.J. Quon Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction Atherosclerosis 209 2010 307 313
45. J. Kim, M. Montagnani, K.K. Koh, and M.J. Quon Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation 113 2006 1888 1904 (Pubitemid 43739401)
46. S.H. Han, M.J. Quon, and K.K. Koh Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction Curr Opin Lipidol 18 2007 58 65 (Pubitemid 46090239)
47. K.K. Koh, S.M. Park, and M.J. Quon Leptin and cardiovascular disease: response to therapeutic interventions Circulation 117 2008 3238 3249
48. P.J. Barter, K.A. Rye, and J.C. Tardif Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial Circulation 124 2011 555 562
49. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150
50. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2